1. ALLA AKTIER
  2. NYHETER
  3. XSPRAY PHARMA

Xspray Pharma

Nyheter Xspray Pharma Nyheter alla bolag
Affiliate
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

Xspray Pharma to host a conference call regarding Nilopki™

Xspray Pharma invites investors, analysts and media to a conference call (in English) on Monday, June 8, 2026, at 3:00 PM CET due to the news communicated on the night of today June 5, regarding the CRL received from the FDA for Nilopki™. The conference call will be hosted by CEO Blake Leitch and CSO Per Andersson.

If you wish to participate via the webcast, please use the link below. Via the webcast, there is an opportunity to ask written questions.
 
https://xspray.events.inderes.com/presskonferens-8-juni-2026
 
If you wish to ask questions orally via telephone conference, please register via the link below. After registration, you will receive a telephone number and a conference ID to log in to the conference call.
 
https://events.inderes.com/xspray/presskonferens-8-juni-2026/dial-in
 

For further information, please contact:

Jacob Nyberg, IRO
Xspray Pharma AB (publ)
Tel: + 46 (0) 70 767 08 83
E-mail: ir@xspray.com

About Xspray Pharma

Xspray Pharma AB (publ) is a pharmaceutical company with several product candidates in clinical development utilizing its innovative, patent protected HyNap™ technology platform to create improved versions of marketed protein kinase inhibitors (PKI), the largest oncology market segment, often with high drug prices. The company’s goal is to become the market leader in improved PKI’s for cancer treatment. Xspray Pharma’s lead drug candidate, Dasynoc® and Nilopki® (an optimized version of Tasigna®) are currently undergoing FDA review. Dasynoc is an amorphous form of dasatinib, demonstrating bioequivalence at a 30% lower dose due to a better solubility profile. Its compatibility with proton pump inhibitors (PPIs), which are often co-prescribed to patients with CML and ALL, is a significant advantage. Xspray Pharma is building a robust product portfolio, including Nilopki and XS008-axitinib (an optimized version of Inlyta®) and XS025-cabozantinib (an optimized version of Cabometyx®).

The Xspray Pharma AB-share is trading at Nasdaq Stockholm (Nasdaq Stockholm: XSPRAY).
www.xspraypharma.com.

Attachments

Xspray Pharma to host a conference call regarding Nilopki™

Datum 2026-06-05, kl 16:48
Källa MFN
Bifogade filer
Xspray Pharma to host a conference call regarding Nilopki™